Clover Appoints LiongHo Chua as President of Greater China
SHANGHAI, China, April 27, 2022 (GLOBE NEWSWIRE) -- Clover Biopharmaceuticals, Ltd. (Clover; HKEX: 02197), a global clinical-stage biotechnology company developing novel vaccines and biologic therapeutic candidates, today announced the appointment of Mr. LiongHo Chua as President of Greater China.
- SHANGHAI, China, April 27, 2022 (GLOBE NEWSWIRE) -- Clover Biopharmaceuticals, Ltd. (Clover; HKEX: 02197), a global clinical-stage biotechnology company developing novel vaccines and biologic therapeutic candidates, today announced the appointment of Mr. LiongHo Chua as President of Greater China.
- "I am grateful for the opportunity to join Clover and advance the important efforts to potentially commercialize our differentiated, protein-based COVID-19 vaccine candidate in China, where we believe we can make a significant impact in the fight against the ongoing COVID-19 outbreaks, said LiongHo Chua, President of Greater China of Clover.
- Prior to joining Clover, Mr. Chua served as the Executive President and Chief Strategy Officer for AIM Vaccine, a leading vaccines manufacturer in China.
- Earlier in his career, Mr. Chua was the General Manager for Sanofi Pasteur China.